These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 25342151)

  • 1. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART).
    Viswanathan S; Detels R; Mehta SH; Macatangay BJ; Kirk GD; Jacobson LP
    AIDS Behav; 2015 Apr; 19(4):601-11. PubMed ID: 25342151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    CMAJ; 2003 Sep; 169(7):656-61. PubMed ID: 14517122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of injecting drug use on response to highly active antiretroviral treatment in HIV-1-infected patients: a nationwide population-based cohort study.
    Larsen MV; Omland LH; Gerstoft J; Røge BT; Larsen CS; Pedersen G; Obel N; Kronborg G
    Scand J Infect Dis; 2010 Dec; 42(11-12):917-23. PubMed ID: 20840000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.
    Rodríguez-Arenas MA; Jarrín I; del Amo J; Iribarren JA; Moreno S; Viciana P; Peña A; Sirvent JL; Vidal F; Lacruz J; Gutierrez F; Oteo JA; Asencio R; Castilla J; Hoyos SP;
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):715-23. PubMed ID: 16910826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy.
    Viswanathan S; Justice AC; Alexander GC; Brown TT; Gandhi NR; McNicholl IR; Rimland D; Rodriguez-Barradas MC; Jacobson LP
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):493-8. PubMed ID: 25886923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with optimal pharmacy refill adherence for antiretroviral medications and plasma HIV RNA non-detectability among HIV-positive crack cocaine users: a prospective cohort study.
    Hayashi K; Wood E; Kerr T; Dong H; Nguyen P; Puskas CM; Guillemi S; Montaner JS; Milloy MJ
    BMC Infect Dis; 2016 Aug; 16(1):455. PubMed ID: 27568002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.
    Weber R; Huber M; Rickenbach M; Furrer H; Elzi L; Hirschel B; Cavassini M; Bernasconi E; Schmid P; Ledergerber B;
    HIV Med; 2009 Aug; 10(7):407-16. PubMed ID: 19490174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
    Palepu A; Tyndall MW; Joy R; Kerr T; Wood E; Press N; Hogg RS; Montaner JS
    Drug Alcohol Depend; 2006 Sep; 84(2):188-94. PubMed ID: 16542797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
    Nolan S; Milloy MJ; Zhang R; Kerr T; Hogg RS; Montaner JS; Wood E
    AIDS Care; 2011 Aug; 23(8):980-7. PubMed ID: 21480010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in sexual and drug-related risk behavior following antiretroviral therapy initiation among HIV-infected injection drug users.
    Fu TC; Westergaard RP; Lau B; Celentano DD; Vlahov D; Mehta SH; Kirk GD
    AIDS; 2012 Nov; 26(18):2383-91. PubMed ID: 23079804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study.
    Weber R; Huber M; Battegay M; Stähelin C; Castro Batanjer E; Calmy A; Bregenzer A; Bernasconi E; Schoeni-Affolter F; Ledergerber B;
    HIV Med; 2015 Mar; 16(3):137-51. PubMed ID: 25124393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.
    Navarro J; Pérez M; Curran A; Burgos J; Feijoo M; Torrella A; Caballero E; Ocaña I; Ribera E; Crespo M; Falcó V
    AIDS Patient Care STDS; 2014 Oct; 28(10):537-42. PubMed ID: 25111167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
    Palepu A; Tyndall M; Yip B; O'Shaughnessy MV; Hogg RS; Montaner JS
    J Acquir Immune Defic Syndr; 2003 Apr; 32(5):522-6. PubMed ID: 12679704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.
    Anema A; Kerr T; Milloy MJ; Feng C; Montaner JS; Wood E
    AIDS Care; 2014 Apr; 26(4):459-65. PubMed ID: 24015838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens.
    Horberg M; Silverberg M; Hurley L; Delorenze G; Quesenberry C
    AIDS Patient Care STDS; 2008 Apr; 22(4):301-12. PubMed ID: 18338961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harm reduction intensity-Its role in HAART adherence amongst drug users in Amsterdam.
    Lambers FA; Stolte IG; van den Berg CH; Coutinho RA; Prins M
    Int J Drug Policy; 2011 May; 22(3):210-8. PubMed ID: 21392958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of drug abuse treatment modalities on adherence to ART/HAART among a cohort of HIV seropositive women.
    Kapadia F; Vlahov D; Wu Y; Cohen MH; Greenblatt RM; Howard AA; Cook JA; Goparaju L; Golub E; Richardson J; Wilson TE
    Am J Drug Alcohol Abuse; 2008; 34(2):161-70. PubMed ID: 18293232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.